Following the announcement that NICE will amend its appraisal processes, there have been several press releases and responses to the news.
Chief Executive of NICE Sir Andrew Dillon said:
“We believe these and the other changes that have now been approved will enhance our ability to optimise access to innovative treatments in the light of the significant financial challenge facing the NHS.”
However, Steve Bates, CEO of the UK BioIndustry Association said:
“Today’s decision by NICE and NHS England to implement this new policy in just two and half weeks’ time sends an immediate, stark, negative signal to the global life science investors and companies that the UK needs to attract in the Brexit era.”
ABPI Chief Executive Mike Thompson commented that:
“Today’s proposals from NICE/NHS England break the Conservative Party’s 2015 Manifesto promise to speed up the introduction of cost-effective medicines into the NHS. No other area of the NHS has the same high levels of scrutiny as medicines. These new plans will prevent patients from receiving NICE approved, cost-effective medicines, undermining their basic rights under the NHS constitution.”